Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.65
+0.08 (0.93%)
At close: May 23, 2025, 4:00 PM
8.95
+0.30 (3.47%)
After-hours: May 23, 2025, 7:49 PM EDT
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $20.40M in the quarter ending March 31, 2025, with 495.65% growth. This brings the company's revenue in the last twelve months to $40.59M, up 46.47% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$40.59M
Revenue Growth
+46.47%
P/S Ratio
10.51
Revenue / Employee
$687,932
Employees
59
Market Cap
472.98M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ZVRA News
- 3 days ago - All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees - GlobeNewsWire
- 10 days ago - Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call - GlobeNewsWire
- 5 weeks ago - Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewsWire
- 6 weeks ago - Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Files Preliminary Proxy - GlobeNewsWire
- 2 months ago - Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewsWire